Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
The protein kinase C (PKC) family has been implicated as second messengers in mechanosensitive modulation of cardiac hypertrophy. However, little information is available on the role of expression and activation of specific cardiac PKC isozymes during development of left ventricular hypertrophy (LVH) and failure (LVF). Dahl salt-sensitive rats fed an 8% salt diet developed systemic hypertension and concentric LVH at 11 weeks of age that is followed by left ventricle (LV) dilatation and global hypokinesis at 17 weeks. Among several PKC isozymes expressed in the LV myocardium, only PKC epsilon showed a 94% increase at the LVH stage. At the LVF stage, however, PKC epsilon returned to the control level, whereas PKC beta I and beta II increased by 158% and 155%, respectively. Hearts were studied at each stage using the Langendorff set-up, and a LV balloon was inflated to achieve an equivalent diastolic wall stress. Following mechanical stretch, PKC epsilon was significantly activated in LVH myocardium in which tissue angiotensin II levels were increased by 59%. Pre-treatment with valsartan, an AT(1)-receptor blocker, abolished the stretch-mediated PKC epsilon activation. Mechanical stretch no longer induced PKC epsilon activation in LVF. Chronic administration of valsartan blunted the progression of LVF and inhibited the increase in PKC beta. Mechanosensitive PKC epsilon activation is augmented and therefore may contribute to the development of compensatory hypertrophy. This effect was dependent on activation of tissue angiotensin II. However, this compensatory mechanism becomes inactive in LVF, where PKC beta may participate in the progression to cardiac dysfunction and LV remodeling.
Inagaki
Koichi
K
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin, Sakyo, Kyoto 606-8507, Japan.
Iwanaga
Yoshitaka
Y
Sarai
Nobuaki
N
Onozawa
Yoko
Y
Takenaka
Hiroyuki
H
Mochly-Rosen
Daria
D
Kihara
Yasuki
Y
D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure; D006332:Cardiomegaly / Q000201:enzymology / Q000378:metabolism* / Q000503:physiopathology; D018450:Disease Progression; D004452:Echocardiography; D004789:Enzyme Activation / Q000187:drug effects; D006333:Heart Failure / Q000201:enzymology / Q000378:metabolism* / Q000503:physiopathology; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009206:Myocardium / Q000473:pathology; D009929:Organ Size; D011493:Protein Kinase C / Q000378:metabolism*; D064546:Protein Kinase C beta; D051744:Protein Kinase C-epsilon; D021381:Protein Transport; D051381:Rats; D020303:Rats, Inbred Dahl; D013314:Stress, Mechanical; D013777:Tetrazoles / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan; D016277:Ventricular Function, Left / Q000187:drug effects
D000959:Antihypertensive Agents; D013777:Tetrazoles; D000804:Angiotensin II; D000068756:Valsartan; C497257:Prkce protein, rat; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D051744:Protein Kinase C-epsilon; D014633:Valine